Literature DB >> 24080855

The EFEMP1 gene: a frequent target for epigenetic silencing in multiple human pituitary adenoma subtypes.

Cuong V Duong1, Kiren Yacqub-Usman, Richard D Emes, Richard N Clayton, William E Farrell.   

Abstract

BACKGROUND/AIMS: In a genome-wide investigation we recently identified the EGF-containing fibulin-like extracellular matrix protein 1 gene, EFEMP1, as hypermethylated in growth hormone-secreting adenoma.
METHODS: In an independent cohort we determined expression of EFEMP1, CpG island methylation and histone tail modification status. The causal consequences of epigenetic modification were determined through epidrug-induced reversal and enforced EFEMP1 expression in GH3 cells.
RESULTS: The majority of adenomas, irrespective of subtype, show reduced EFEMP1 expression. However, epigenetic change, as determined by CpG island methylation, was not invariantly associated with decreased EFEMP1 expression. Conversely, chromatin immunoprecipitation assays revealed enrichment for modifications associated with either active or silenced genes in adenoma that did or did not express EFEMP1 respectively. In AtT-20 and GH3 cells a causal relationship between epigenetic silencing and expression of EFEMP1 was established where co-incubation with the epidrugs zebularine and TSA induced expression of EFEMP1 and concomitant histone tail modifications toward those associated with expressed genes. Enforced expression of EFEMP1 in GH3 cells was without effect on cell proliferation or apoptotic end-points, however inhibition of endogenous matrix metalloproteinase (MMP)-2 expression was apparent. Primary adenomas did not show this relationship, however a positive correlation was apparent with the MMP7 transcript and perhaps reflects cell or species differences.
CONCLUSIONS: The protein product of the EFEMP1 gene, fibulin-3, is reported to impact on multiple pathways in a cell-specific context. Subtype-independent loss of EFEMP1 expression in the majority of primary adenomas should prompt more detailed investigation in this tumour type.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24080855     DOI: 10.1159/000355624

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  6 in total

Review 1.  Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.

Authors:  Busra Aydin; Aysegul Caliskan; Kazim Yalcin Arga
Journal:  EPMA J       Date:  2021-06-26       Impact factor: 8.836

2.  A genome-wide association study identifies four novel susceptibility loci underlying inguinal hernia.

Authors:  Eric Jorgenson; Nadja Makki; Ling Shen; David C Chen; Chao Tian; Walter L Eckalbar; David Hinds; Nadav Ahituv; Andrew Avins
Journal:  Nat Commun       Date:  2015-12-21       Impact factor: 14.919

Review 3.  Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-"Are We There Yet?"

Authors:  Lydia S Lamb; Hao-Wen Sim; Ann I McCormack
Journal:  Cancers (Basel)       Date:  2020-01-28       Impact factor: 6.639

4.  Differential Epigenetic Status and Responses to Stressors between Retinal Cybrids Cells with African versus European Mitochondrial DNA: Insights into Disease Susceptibilities.

Authors:  Shari R Atilano; Sina Abedi; Narcisa V Ianopol; Mithalesh K Singh; J Lucas Norman; Deepika Malik; Payam Falatoonzadeh; Marilyn Chwa; Anthony B Nesburn; Baruch D Kuppermann; M Cristina Kenney
Journal:  Cells       Date:  2022-08-26       Impact factor: 7.666

5.  EZH2 is highly expressed in pituitary adenomas and associated with proliferation.

Authors:  David Schult; Annett Hölsken; Sonja Siegel; Michael Buchfelder; Rudolf Fahlbusch; Ilonka Kreitschmann-Andermahr; Rolf Buslei
Journal:  Sci Rep       Date:  2015-11-23       Impact factor: 4.379

6.  T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma.

Authors:  Sheng Zhong; Bo Wu; Jiahui Li; Xinhui Wang; Shanshan Jiang; Fangfei Hu; Gaojing Dou; Yuan Zhang; Chunjia Sheng; Gang Zhao; Yunqian Li; Yong Chen
Journal:  Aging (Albany NY)       Date:  2019-10-26       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.